Cytodyn Incis A Clinical Stage Biotechnology Company Based In Vancouverwashingtonfounded In 2002The Company Focuses On Developing Therapies That Target The Ccr5 Receptorits Lead Candidateleronlimabpro 140 Is A Humanized Monoclonal Antibody With Applications In Oncologyinflammationand Infectious Diseasesincluding Hiv Treatment And Prevention The Company Has Conducted Over 30 Clinical Trialsparticularly Emphasizing Oncology And Inflammatory Conditionsleronlimab Is Currently Being Studied For Various Cancersincluding Colorectal Cancer And Breast Canceras Well As For Reducing Inflammatory Responses In Conditions Like Liver Fibrosiscytodyn Is Also Developing A Long Acting Formulation Of Leronlimab To Enhance Its Therapeutic Potentialthe Company Collaborates With Other Pharmaceutical And Biotechnology Firms To Advance Its Development Efforts
